Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Finished Goods (2016 - 2025)

Historic Finished Goods for Guided Therapeutics (GTHP) over the last 15 years, with Q1 2025 value amounting to $818000.0.

  • Guided Therapeutics' Finished Goods changed 0.0% to $818000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $818000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $818000.0 for FY2024, which is 0.0% changed from last year.
  • Latest data reveals that Guided Therapeutics reported Finished Goods of $818000.0 as of Q1 2025, which was down 0.0% from $818000.0 recorded in Q4 2024.
  • Guided Therapeutics' 5-year Finished Goods high stood at $818000.0 for Q4 2022, and its period low was $758000.0 during Q1 2021.
  • For the 5-year period, Guided Therapeutics' Finished Goods averaged around $801235.3, with its median value being $818000.0 (2022).
  • Its Finished Goods has fluctuated over the past 5 years, first crashed by 954.65% in 2021, then skyrocketed by 420.38% in 2022.
  • Over the past 5 years, Guided Therapeutics' Finished Goods (Quarter) stood at $785000.0 in 2021, then grew by 4.2% to $818000.0 in 2022, then changed by 0.0% to $818000.0 in 2023, then changed by 0.0% to $818000.0 in 2024, then changed by 0.0% to $818000.0 in 2025.
  • Its Finished Goods was $818000.0 in Q1 2025, compared to $818000.0 in Q4 2024 and $818000.0 in Q3 2024.